Idiopathic pulmonary fibrosis is a chronic progressive lung disease, in which the functional gas exchanging tissue of the lungs is replaced with connective tissue, and is characterized by histopathological pattern of usual interstitial pneumonia. The mortality ranges from 78.6 to 188.6 per 1000 patient/years depending on the disease severity. Currently, the IPF patients have very few treatment options. In EU and US only two drugs, pirfenidone and nintedanib, have been approved for clinical use.[3–5] The available drugs are also associated with adverse effects which significantly decrease the quality of life of the patients. In the clinical trials on pirfenidone, the CAPACITY studies, 98% of patients on pirfenidone reported at least one adverse effect, of which most common were gastrointestinal symptoms, skin related adverse effects and dizziness. In the clinical trials on nintedanib, the INPULISIS studies, over 90% of the patients on nintedanib reported diarrhea as treatment-emergent adverse effect.